Esperion Therapeutics, Inc. (ESPR)

NASDAQ: ESPR · IEX Real-Time Price · USD

2.390

-0.060 (-2.45%)

At close: Jul 19, 2024, 4:00 PM

2.430

+0.040 (1.67%)

Pre-market: Jul 22, 2024, 9:02 AM EDT

Esperion Therapeutics Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Year Ending	TTM	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019	2018 - 2011
Net Income	-86.51	-209.25	-233.66	-269.11	-143.55	-97.17	Upgrade
Depreciation & Amortization	0.08	0.16	0.5	0.61	0.55	0.32	Upgrade
Share-Based Compensation	12.29	11.96	15.22	24.31	28.39	25.88	Upgrade
Other Operating Activities	46.83	61.64	43.12	-19.62	29.44	0.62	Upgrade
Operating Cash Flow	-27.3	-135.49	-174.83	-263.81	-85.18	-70.34	Upgrade
Capital Expenditures	-0.07	0	0	0	-0.87	-0.95	Upgrade
Acquisitions	0	0	0	0	-12.5	0	Upgrade
Change in Investments	17.5	42.5	8.1	-50.48	34.73	65.18	Upgrade
Investing Cash Flow	17.43	42.5	8.1	-50.48	21.36	64.23	Upgrade
Share Issuance / Repurchase	109.79	65.95	90.85	222.45	-48.37	11.77	Upgrade
Debt Issued / Paid	-18.23	-15.51	-58.02	46.09	250.09	124.42	Upgrade
Other Financing Activities	0.02	0.02	-0.22	-0.32	-	-	Upgrade
Financing Cash Flow	91.57	50.46	32.61	268.22	201.73	136.2	Upgrade
Net Cash Flow	81.7	-42.53	-134.12	-46.07	137.9	130.09	Upgrade
Free Cash Flow	-27.38	-135.49	-174.83	-263.81	-86.05	-71.29	Upgrade
Free Cash Flow Margin	-11.92%	-116.46%	-231.64%	-336.29%	-37.81%	-48.05%	Upgrade
Free Cash Flow Per Share	-0.16	-1.31	-2.63	-9.13	-3.13	-2.63	Upgrade

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).